Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q4 EPS of $0.47, $0.85 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $199.91 million versus the consensus estimate of $198.82 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.